Clinical Trials
60 trialsImmune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Tianjin Medical University Cancer Institute and Hospital
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Sun Yat-sen University
RADICAL
Beijing Friendship Hospital
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
West China Hospital
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Shandong Cancer Hospital and Institute
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients
Nanfang Hospital, Southern Medical University
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Hebei Medical University Fourth Hospital
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
SCR-ESCC-01
Shanghai Chest Hospital
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Fudan University
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
The University of Hong Kong
SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer
Sun Yat-sen University
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
The First Affiliated Hospital of Zhengzhou University
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Tongji Hospital
Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases
China Medical University, China
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
AGAMENON
Fundación Sociedad Española de Oncologia Médica
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
Fudan University
ONTRESCC
Peking Union Medical College Hospital
C-MSI
Gruppo Oncologico Italiano di Ricerca Clinica
BTCICTY-001
Zhongda Hospital
ICC
University of Alabama at Birmingham
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
Zhejiang Cancer Hospital
iMHRT-LARC
Shanghai Zhongshan Hospital
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Fudan University
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
REICRAE
Tianjin Medical University Cancer Institute and Hospital
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
Qianfoshan Hospital
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma
University of Malaya
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
Fujian Medical University Union Hospital
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Peking University Third Hospital
AK104-IIT-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TREE
The Central Hospital of Lishui City
NACSOC-02
Beijing Chao Yang Hospital
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
The Second Hospital of Shandong University
Miracle-1
Fudan University
CRATER
University of Kentucky
RECORD
Chinese PLA General Hospital
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
WATCHER
Zhejiang Cancer Hospital